Pioglitazone might prevent the progression of slowly progressive type 1 diabetes

Yoshinaga Kawano, Junichiro Irie, Hiroshi Nakatani, Satoru Yamada

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Although recent studies recommended that insulin should be administered to patients with slowly progressive type 1 diabetes, even those with non-insulin dependent status, patients prefer oral hypoglycemic agents to insulin injections. We report a slowly progressive type 1 diabetic patient whose insulin production was preserved for 4 years (ΣC-peptide from 29.48 ng/mL to 24.58 ng/mL) using pioglitazone despite a high titer of anti-GAD antibody (GADA; 120.7 U/mL). This case suggests that pioglitazone might prevent or delay the loss of insulin secretion and insulin dependency in slowly progressive type 1 diabetic patients.

Original languageEnglish
Pages (from-to)1037-1039
Number of pages3
JournalInternal Medicine
Issue number12
Publication statusPublished - 2009


  • Anti-GAD antibody
  • PPAR-γ
  • Pioglitazone
  • Slowly progressive type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Pioglitazone might prevent the progression of slowly progressive type 1 diabetes'. Together they form a unique fingerprint.

Cite this